CompletedNot Applicable

EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso

Burkina Faso58 participantsStarted 2011-02-21

Plain-language summary

This is a pre-post randomized community-based controlled trial aimed at estimating the effectiveness of an educational package developed using PRECEDE PROCEED to reduce the cumulative incidence of Taenia solium cysticercosis in three Provinces of Burkina Faso. The study design included an 18-months baseline study to measure baseline cumulative incidence of cysticercosis followed by an 18-month post randomization study to measure the effectiveness of the intervention. Sixty villages of three Provinces of Burkina Faso were included. The primary outcome was the change in the baseline to post randomization cumulative incidence in the intervention group compared to the control group.

Who can participate

Age range

5 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

The unit of randomization and analysis of this study is the village. Therefore, the eligibility criteria were determined at the village level. Inclusion Criteria: * Population of at least 1000 at the 2006 census * Present on the map of the "Institut Géographique du Burkina 2000" * Separated from another village by at least 5 kilometers. Exclusion Criteria: * Village located on a National or Provincial road * Village located within 20 km of Koudougou or Ouagadougou * Regional or Provincial Capital * Absence of pigs in the village At the individual level, the following eligibility criteria were used: Inclusion Criteria: * Aged 5 years old or more * Has lived in the village for at least 12 months * Not planning to move in the next three years Exclusion Criteria: * Presence of confirmed epilepsy or progressively worsening severe chronic headaches at baseline.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Human active cysticercosis cumulative incidence

Timeframe: baseline, 18 months follow-up pre randomization, 18 months follow-up post randomization

Trial details

NCT IDNCT03095339

SponsorUniversity of Oklahoma

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-11-24

View on ClinicalTrials.gov More Cysticercosis trials